Circulating MicroRNAs as biomarkers for hepatocellular carcinoma

Journal of Clinical Gastroenterology

Volumn 45, Issue 4, 2011, Pages 355-360

  Qu, Kevin Z ^a   Zhang, Ke ^a   Li, Hairong ^a   Afdhal, Nezam H ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

fetoprotein; fetoprotein L3; des g carboxyprothrombin (DCP); hepatocellular carcinoma; microRNA

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; MICRORNA; MICRORNA 16; MICRORNA 195; MICRORNA 199A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; FEMALE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952813995     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181f18ac2     Document Type: Article

References (40)

1. Ei-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. (Pubitemid 46890874)
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156. (Pubitemid 32911406)
3. Benson AB III, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391.
4. Lee YS, Dutta A. Micro RNAs in cancer. Annu Rev Pathol. 2009;4:199-227.
5. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene target. Proc Natl Acad Sci USA. 2006;103:2257-2261. (Pubitemid 43271657)
6. Esquela-Kerscher A, Slack FJ. OncomiRs\microRNA with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
7. Gramantier L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12:2189-2204.
8. Kloosterman W, Plasterk R. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441-450. (Pubitemid 44430905)
9. Stefani G, Slack F. Small noncoding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9:219-230. (Pubitemid 351301826)
10. Zamore P, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519-1524. (Pubitemid 41266468)
11. Calin G, Dumitru C, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524-15529. (Pubitemid 35403967)
12. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838. (Pubitemid 40839735)
13. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression pattern in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25: 2537-2545.
14. Huang YS, Gai Y, Yu XF, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissue without vial hepatitis. J Gastroenterol Hepatol. 2008;23:87-94.
15. Meng F, Henson R, Wehbe-Janck H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133: 647-658. (Pubitemid 47187346)
16. Jiang J, Gusev Y, Aderca I, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infec-tion, cirrhosis, and patient survival. Clin Cancer Res. 2008;14: 419-427. (Pubitemid 351226109)
17. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 control CDKN1C/p57 and CDKN1b/p27 expression in human hepa-tocellular carcinoma. Oncogene. 2008;27:5651-5661.
18. Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008; 68:2773-2780. (Pubitemid 351556275)
19. Pei Y, Zhang T, Renault V, et al. An overview of hepato-cellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin. 2009;41:1-15.
20. Kim S, Lee UJ, Kim MN, et al. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extra-cellular signal-regulated kinase 2 (ERK2). J Biol Chem. 2008; 283:18158-18166.
21. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007;67: 6092-6099. (Pubitemid 47037488)
22. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36.
23. Cortez M, Calin G. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9:703-711.
24. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detec-tion. Proc Natl Acad Sci USA. 2008;105:10513-10518.
25. Lawrie C, Gal S, Dunlop H, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;14: 672-675. (Pubitemid 351667616)
26. Zhu W, Qin W, Atasoy U, et al. Circulating microRNA in breast cancer and healthy subjects. BMC Res Notes. 2009;2:89.
27. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126.
28. Guo CJ, Pan Q, Li DG, et al. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol. 2009;50:766-778.
29. Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:111-117. (Pubitemid 43129532)
30. Volk ML, Hernandez JC, Su GL, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3:79-87. (Pubitemid 47103809)
31. Bruix J, Sherman M, Practice Guidelines Committee, Amer-ican Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
32. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102-114.
33. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Cell. 2007;131:1109-1169.
34. Calin G, Croce C MicroRNA signature in human cancer. Nat Rev Cancer. 2006;6:857-866. (Pubitemid 44629897)
35. Braconi C, Patel T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology. 2008;47:1807-1809. (Pubitemid 351945546)
36. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008; 47:1955-1963. (Pubitemid 351952843)
37. Bonci D, Coppola V, Musumeci M, et al. The miR-15a and miR-16-1 cluster controls prostate cancer progression by targeting multiple oncogenic activities. Nat Med. 2008;14: 1271-1277.
38. Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005; 204:280-285. (Pubitemid 40776831)
39. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010;17:215-220.
40. Guo CJ, Pan Q, Jiang B, et al. Effects of upregulated expres-sion of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis. 2009;14:1331-1340.